This trial is a phase 3 study to evaluate efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.~In Rosuvastatin/Ezetimibe+Telmisartan/Amlodipine treatment group, 48 subjects will be assigned and the subjects administer Rosuvastatin/Ezetimibe+Telmisartan/Amlodipine for 8 weeks.~In Rosuvastatin/Ezetimibe +Telmisartan  treatment group, 48 subjects will be assigned and the subjects administer Rosuvastatin/Ezetimibe+Telmisartan for 8 weeks.~In Telmisartan/Amlodipine treatment group, 48 subjects will be assigned and the subjects administer Telmisartan/Amlodipine for 8 weeks.
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine in patients with primary hypercholesterolemia and essential hypertension.